DecBio conducted 10 interviews with KOLs at academic medical centers, pharmaceutical companies, reference labs, and CROs to better understand their perception of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS.

DeciBio conducted 11 interviews with KOLs at pharmaceutical companies to understand how pharma spends their money in support of therapeutic / precision medicine development initiatives today, and how these investments may change in the future

DeciBio conducted 10 interviews with academic researchers and biopharma executives to explore how advanced and next-generation proteomics tools have been adopted into research efforts today

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care